Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden

Nahi, Hareth ; Walinder, Göran ; Patel, Vishal ; Qu, Ying ; Levine, Aaron ; Majer, Istvan ; Kutikova, Lucie ; Hellqvist Franck, Eva ; Svensson, Maria K. and Hansson, Markus LU orcid (2021) In Acta Haematologica 144(5). p.519-527
Abstract

Introduction: Treatment-induced peripheral neuropathy (TIPN) is a complication of multiple myeloma (MM) treatment. Objective: This real-world, retrospective study used electronic medical record (EMR) data from 3 Swedish clinics to assess the occurrence and economic burden of TIPN in patients with MM. Methods: Eligible patients had an MM diagnosis in the Swedish Cancer Registry between 2006 and 2015 and initiated treatment during that period. Follow-up was until last EMR visit, death, or study end (April 2017). The current analyses included patients receiving bortezomib, lenalidomide, carfilzomib, or thalidomide at any treatment line. To discern healthcare resource utilization (HCRU) and costs associated with TIPN from other causes,... (More)

Introduction: Treatment-induced peripheral neuropathy (TIPN) is a complication of multiple myeloma (MM) treatment. Objective: This real-world, retrospective study used electronic medical record (EMR) data from 3 Swedish clinics to assess the occurrence and economic burden of TIPN in patients with MM. Methods: Eligible patients had an MM diagnosis in the Swedish Cancer Registry between 2006 and 2015 and initiated treatment during that period. Follow-up was until last EMR visit, death, or study end (April 2017). The current analyses included patients receiving bortezomib, lenalidomide, carfilzomib, or thalidomide at any treatment line. To discern healthcare resource utilization (HCRU) and costs associated with TIPN from other causes, patients with TIPN were matched with those without on baseline characteristics, treatment, and line of therapy. All analyses were descriptive. Results: Overall, 457 patients were included; 102 (22%) experienced TIPN. Patients experiencing TIPN during first-line treatment mostly received bortezomib-based regimens (n = 48/57 [84%]); those with TIPN during second- A nd third/fourth-line treatment mostly received lenalidomide/thalidomide-based regimens (19/31 [61%], 8/14 [57%], respectively). Patients with TIPN had higher HCRU/costs than those without TIPN (mean differences in hospital outpatient visits: 5.2, p = 0.0031; total costs per patient-year: EUR 17,183, p = 0.0007). Conclusions: Effective MM treatments associated with a reduced incidence of TIPN could result in decreased healthcare expenditure.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Healthcare costs, Healthcare resource utilization, Multiple myeloma, Treatment-induced peripheral neuropathy
in
Acta Haematologica
volume
144
issue
5
pages
519 - 527
publisher
Karger
external identifiers
  • scopus:85102250696
  • pmid:33631745
ISSN
0001-5792
DOI
10.1159/000512165
language
English
LU publication?
yes
id
202d220a-6427-4e65-9734-c62ba2159393
date added to LUP
2021-03-29 13:39:24
date last changed
2024-06-01 08:07:52
@article{202d220a-6427-4e65-9734-c62ba2159393,
  abstract     = {{<p>Introduction: Treatment-induced peripheral neuropathy (TIPN) is a complication of multiple myeloma (MM) treatment. Objective: This real-world, retrospective study used electronic medical record (EMR) data from 3 Swedish clinics to assess the occurrence and economic burden of TIPN in patients with MM. Methods: Eligible patients had an MM diagnosis in the Swedish Cancer Registry between 2006 and 2015 and initiated treatment during that period. Follow-up was until last EMR visit, death, or study end (April 2017). The current analyses included patients receiving bortezomib, lenalidomide, carfilzomib, or thalidomide at any treatment line. To discern healthcare resource utilization (HCRU) and costs associated with TIPN from other causes, patients with TIPN were matched with those without on baseline characteristics, treatment, and line of therapy. All analyses were descriptive. Results: Overall, 457 patients were included; 102 (22%) experienced TIPN. Patients experiencing TIPN during first-line treatment mostly received bortezomib-based regimens (n = 48/57 [84%]); those with TIPN during second- A nd third/fourth-line treatment mostly received lenalidomide/thalidomide-based regimens (19/31 [61%], 8/14 [57%], respectively). Patients with TIPN had higher HCRU/costs than those without TIPN (mean differences in hospital outpatient visits: 5.2, p = 0.0031; total costs per patient-year: EUR 17,183, p = 0.0007). Conclusions: Effective MM treatments associated with a reduced incidence of TIPN could result in decreased healthcare expenditure.</p>}},
  author       = {{Nahi, Hareth and Walinder, Göran and Patel, Vishal and Qu, Ying and Levine, Aaron and Majer, Istvan and Kutikova, Lucie and Hellqvist Franck, Eva and Svensson, Maria K. and Hansson, Markus}},
  issn         = {{0001-5792}},
  keywords     = {{Healthcare costs; Healthcare resource utilization; Multiple myeloma; Treatment-induced peripheral neuropathy}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{519--527}},
  publisher    = {{Karger}},
  series       = {{Acta Haematologica}},
  title        = {{Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden}},
  url          = {{http://dx.doi.org/10.1159/000512165}},
  doi          = {{10.1159/000512165}},
  volume       = {{144}},
  year         = {{2021}},
}